(lp0
S'Albireo Pharma Inc. ALBO  Wall Street Journal - Feb 1, 2001 News Albireo Pharma Inc.ALBO. Significant News Only. 03/07/17; Press Release. Albireo to Host Conference Call and Webcast on March 14 at 8:30 a.m.'
p1
aS"William Blair Weighs in on Albireo Pharma, Inc.'s Q1 2017 Earnings  The Cerbat Gem - 4 hours ago Albireo Pharma logo Albireo Pharma, Inc.  - Equities researchers at William Blair decreased their Q1 2017 earnings estimates for shares of Albireo Pharma in a research report issued to clients and investors on Tuesday."
p2
aS'BRIEF-Albireo Pharma Inc says filed for mixed shelf offering of up to $100 mln Reuters - Dec 22, 2016 BERLIN, Feb 12 Greece and its lenders should quickly approve a review of reforms the indebted country must take in return for unlocking new loans, a senior European Union official said on Sunday, warning of financial instability in the euro zone if the ...'
p3
aS"Albireo Completes Transaction with Biodel to Create Publicly Traded Company ... GlobeNewswire  - Nov 3, 2016 BOSTON, Nov. 03, 2016  -- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators through its operating subsidiary, today announced the completion of the share exchange&nbsp;...Nine stories you may have missed Thursday from the world of business - The Boston GlobeBoston's newest public company, Albireo, aims to treat kids' liver diseases - Boston Business Journal"
p4
aS'ALBIREO PHARMA, INC.  Files An 8-K Departure of Directors or ... Market Exclusive - Jan 27, 2017 On January 23, 2017, the Board of Directors  of Albireo Pharma, Inc. , acting upon the recommendation of the Compensation Committee of the Board , approved an increase in the annual base&nbsp;...'
p5
aS'Boston biotech Albireo goes public in unusual fashion The Boston Globe - Nov 3, 2016 Boston biotech Albireo Pharma Inc. went public Thursday through a reverse merger in which it acquired the stock listing of a Connecticut company, in a deal that will leave Albireo with about $30 million to develop a treatment for a pediatric liver disease.'
p6
aS'Albireo Pharma  Partner Submits NDA for Elobixibat in Japan StreetInsider.com - Feb 1, 2017 Albireo Pharma, Inc.  announced that EA Pharma Co., Ltd. has submitted a New Drug Application  to the Japanese Pharmaceuticals and Medical Devices Agency  for elobixibat for the treatment of chronic constipation in Japan.'
p7
aS'Q1 2017 EPS Estimates for Albireo Pharma, Inc. Decreased by William Blair  Sports Perspectives - Mar 17, 2017 Albireo Pharma logo Albireo Pharma, Inc.  - Investment analysts at William Blair reduced their Q1 2017 EPS estimates for shares of Albireo Pharma in a note issued to investors on Tuesday.'
p8
aS'ALBIREO PHARMA,INC.  Files An 8-K Financial Statements and Exhibits Market Exclusive - Dec 20, 2016 Albireo Pharma, Inc., formerly Biodel Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and ...'
p9
aS'Albireo Reports 2016 Financial Results GlobeNewswire  - Mar 14, 2017 BOSTON, March 14, 2017  -- Albireo Pharma, Inc. , an orphan pediatric liver disease company developing novel bile acid modulators, today announced financial results for the year ended December 31, 2016.'
p10
a.